CPX-351

4 · 20 / page

Ask MedXY AI

Latest news

Tag

Hematology-OncologyAMLCPX-351

CPX-351 Benefit in AML is Driven by Myelodysplasia-Related Mutations: Insights from a Phase 3 Molecular Re-analysis

By MedXY|Feb 18, 2026

A molecular re-evaluation of the pivotal CPX-351 phase 3 trial reveals that its survival benefit is selectively confined to patients with myelodysplasia-related mutations (AML-MR), with no significant advantage over standard 7+3 induction i

CPX‑351 in Down Syndrome–Associated Myeloid Leukemia: a dose‑sensitivity mismatch that reduced event‑free survival in the ML‑DS 2018 trial

Hematology-OncologyCPX-351Down syndrome

CPX-351

Latest news

CPX-351 Benefit in AML is Driven by Myelodysplasia-Related Mutations: Insights from a Phase 3 Molecular Re-analysis

CPX‑351 in Down Syndrome–Associated Myeloid Leukemia: a dose‑sensitivity mismatch that reduced event‑free survival in the ML‑DS 2018 trial

DAGO2 (daunorubicin/cytarabine + fractionated gemtuzumab) Outperforms CPX‑351 in Older Adults with Non‑Adverse‑Risk AML: NCRI AML18 Results

DAGO2 (daunorubicin+cytarabine+fractionated gemtuzumab) outperforms CPX‑351 in older adults with non‑adverse‑risk AML: insights from NCRI AML18